We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the... Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. Show more
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE...
A California-based biotech company found a tremendous amount of success on Tuesday following the company announcing an agreement to divest its Udenyca franchise for $558.4 To read the full story...
- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZIยฎ, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor - - Proceeds to fund...
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.ย (โCoherus,โ NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.18 | -11.0429447853 | 1.63 | 1.75 | 1.35 | 3120152 | 1.5380695 | CS |
4 | 0.225 | 18.3673469388 | 1.225 | 2.43 | 1.19 | 10006778 | 1.64625973 | CS |
12 | 0.41 | 39.4230769231 | 1.04 | 2.43 | 0.6655 | 5371622 | 1.35462435 | CS |
26 | -0.24 | -14.201183432 | 1.69 | 2.43 | 0.6655 | 3532211 | 1.35506979 | CS |
52 | -0.6 | -29.2682926829 | 2.05 | 3.7 | 0.6655 | 3643477 | 1.94174201 | CS |
156 | -16.3 | -91.8309859155 | 17.75 | 17.92 | 0.6655 | 2493731 | 3.88105148 | CS |
260 | -16.87 | -92.0851528384 | 18.32 | 23.03 | 0.6655 | 1897112 | 6.76111721 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions